Roger Barker, PhD - Publications

1992- Brain Repair Centre University of Cambridge, Cambridge, England, United Kingdom 

140 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kaiser K, Gyllborg D, Procházka J, Salašová A, Kompaníková P, Molina FL, Laguna-Goya R, Radaszkiewicz T, Harnoš J, Procházková M, Potěšil D, Barker RA, Casado ÁG, Zdráhal Z, Sedláček R, et al. WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis. Nature Communications. 10: 1498. PMID 30940800 DOI: 10.1038/s41467-019-09298-4  0.6
2018 Maxan A, Mason S, Saint-Pierre M, Smith E, Ho A, Harrower T, Watts C, Tai Y, Pavese N, Savage JC, Tremblay MÈ, Gould P, Rosser AE, Dunnett SB, Piccini P, ... Barker RA, et al. Outcome of cell suspension allografts in a patient with Huntington's disease. Annals of Neurology. PMID 30286516 DOI: 10.1002/ana.25354  1
2018 La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, Lidschreiber K, Kastriti ME, Lönnerberg P, Furlan A, Fan J, Borm LE, Liu Z, van Bruggen D, Guo J, ... ... Barker R, et al. RNA velocity of single cells. Nature. PMID 30089906 DOI: 10.1038/s41586-018-0414-6  0.6
2017 Bao L, Al-Assar O, Drynan LF, Arends MJ, Tyers P, Barker RA, Rabbitts TH. A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS. Scientific Reports. 7: 44899. PMID 28322325 DOI: 10.1038/srep44899  0.92
2016 La Manno G, Gyllborg D, Codeluppi S, Nishimura K, Salto C, Zeisel A, Borm LE, Stott SR, Toledo EM, Villaescusa JC, Lönnerberg P, Ryge J, Barker RA, Arenas E, Linnarsson S. Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells. Cell. 167: 566-580.e19. PMID 27716510 DOI: 10.1016/j.cell.2016.09.027  0.6
2016 Rittman T, Rubinov M, Vértes PE, Patel AX, Ginestet CE, Ghosh BC, Barker RA, Spillantini MG, Bullmore ET, Rowe JB. Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. Neurobiology of Aging. 48: 153-160. PMID 27697694 DOI: 10.1016/j.neurobiolaging.2016.09.001  0.92
2016 Swallow DM, Lawton MA, Grosset KA, Malek N, Klein J, Baig F, Ruffmann C, Bajaj NP, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Morris HR, Williams N, Wood NW, et al. Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 27671901 DOI: 10.1136/jnnp-2016-313642  0.92
2016 Kuan WL, Bennett N, He X, Skepper JN, Martynyuk N, Wijeyekoon R, Moghe PV, Williams-Gray CH, Barker RA. α-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function. Experimental Neurology. PMID 27632900 DOI: 10.1016/j.expneurol.2016.09.003  0.92
2016 Villaescusa JC, Li B, Toledo EM, Rivetti di Val Cervo P, Yang S, Stott SR, Kaiser K, Islam S, Gyllborg D, Laguna-Goya R, Landreh M, Lönnerberg P, Falk A, Bergman T, Barker RA, et al. A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson's disease. The Embo Journal. PMID 27354364 DOI: 10.15252/embj.201593725  0.6
2016 Rae CL, Nombela C, Rodríguez PV, Ye Z, Hughes LE, Jones PS, Ham T, Rittman T, Coyle-Gilchrist I, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Atomoxetine restores the response inhibition network in Parkinson's disease. Brain : a Journal of Neurology. PMID 27343257 DOI: 10.1093/brain/aww138  0.92
2016 Fallon SJ, Hampshire A, Barker RA, Owen AM. Learning to be inflexible: Enhanced attentional biases in Parkinson's disease. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. 82: 24-34. PMID 27318659 DOI: 10.1016/j.cortex.2016.05.005  0.92
2016 Breen DP, Barker RA. Exogenous melatonin for Parkinson's disease: 'Waking up' to the need for further trials. Parkinsonism & Related Disorders. PMID 27215394 DOI: 10.1016/j.parkreldis.2016.05.012  0.92
2016 Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, et al. Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. Stem Cell Reports. PMID 27185282 DOI: 10.1016/j.stemcr.2016.05.001  0.92
2016 Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Collerton D, Taylor JP, Burn DJ. Cognitive decline and quality of life in incident Parkinson's disease: The role of attention. Parkinsonism & Related Disorders. PMID 27094482 DOI: 10.1016/j.parkreldis.2016.04.009  0.92
2016 Zhang J, Nombela C, Wolpe N, Barker RA, Rowe JB. Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27091513 DOI: 10.1002/mds.26631  0.92
2016 Mok KY, Sheerin U, Simón-Sánchez J, Salaka A, Chester L, Escott-Price V, Mantripragada K, Doherty KM, Noyce AJ, Mencacci NE, Lubbe SJ, Williams-Gray CH, Barker RA, van Dijk KD, et al. Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. The Lancet. Neurology. PMID 27017469 DOI: 10.1016/S1474-4422(16)00071-5  0.92
2016 Barker RA, Parmar M, Kirkeby A, Björklund A, Thompson L, Brundin P. Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016? Journal of Parkinson's Disease. PMID 27003785 DOI: 10.3233/JPD-160798  0.92
2016 Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, Cummins GA, Duncan GW, Khoo TK, Burn DJ, Barker RA. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26999434 DOI: 10.1002/mds.26563  0.92
2016 Velseboer DC, de Bie RM, Wieske L, Evans JR, Mason SL, Foltynie T, Schmand B, de Haan RJ, Post B, Barker RA, Williams-Gray CH. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology. PMID 26888991 DOI: 10.1212/WNL.0000000000002437  0.92
2016 Begeti F, Schwab LC, Mason SL, Barker RA. Hippocampal dysfunction defines disease onset in Huntington's disease. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 26833174 DOI: 10.1136/jnnp-2015-312413  0.92
2016 Evans JR, Cummins G, Breen DP, Foltynie T, Mason SL, Brayne CE, Williams-Gray CH, Barker RA. Comparative epidemiology of incident Parkinson's disease in Cambridgeshire, UK. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 26800710 DOI: 10.1136/jnnp-2015-312581  0.92
2016 Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS, Rodríguez PV, Coyle-Gilchrist I, Regenthal R, Altena E, Housden CR, Maxwell H, Sahakian BJ, Barker RA, Robbins TW, et al. Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Human Brain Mapping. PMID 26757216 DOI: 10.1002/hbm.23087  0.92
2016 Barker RA, Williams-Gray CH. The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology. PMID 26750431 DOI: 10.1111/nan.12303  0.92
2016 Thomas MG, Welch C, Stone L, Allan P, Barker RA, White RB. PAX6 expression may be protective against dopaminergic cell loss in Parkinson’s disease Cns and Neurological Disorders - Drug Targets. 15: 73-79.  0.92
2015 Zhang J, Rittman T, Nombela C, Fois A, Coyle-Gilchrist I, Barker RA, Hughes LE, Rowe JB. Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease. Brain : a Journal of Neurology. PMID 26582559 DOI: 10.1093/brain/awv331  0.92
2015 Mason SL, Barker RA. Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature. Expert Opinion On Pharmacotherapy. 1-12. PMID 26536068 DOI: 10.1517/14656566.2016.1109630  0.92
2015 Tedroff J, Waters S, Barker RA, Roos R, Squitieri F. Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease. Journal of Huntington's Disease. 4: 131-40. PMID 26397894 DOI: 10.3233/JHD-150143  0.92
2015 Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease—past insights and future potential. Nature Reviews. Neurology. 11: 492-503. PMID 26240036 DOI: 10.1038/nrneurol.2015.123  0.92
2015 Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, Brooks DJ, Barker RA, Burn DJ, O'Brien JT. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26202802 DOI: 10.1002/mds.26312  0.92
2015 Cox TM, Rosenbloom BE, Barker RA. Gaucher disease and comorbidities: B-cell malignancy and parkinsonism. American Journal of Hematology. 90: S25-8. PMID 26096744 DOI: 10.1002/ajh.24057  0.92
2015 Kim JI, Long JD, Mills JA, McCusker E, Paulsen JS. Multivariate Clustering of Progression Profiles Reveals Different Depression Patterns in Prodromal Huntington Disease. Neuropsychology. PMID 26011117 DOI: 10.1037/neu0000199  0.92
2015 Poole E, Kuan WL, Barker R, Sinclair J. The human cytomegalovirus non-coding Beta2.7 RNA as a novel therapeutic for Parkinson's disease - Translational research with no translation. Virus Research. PMID 26003955 DOI: 10.1016/j.virusres.2015.05.007  0.92
2015 Vuono R, Winder-Rhodes S, de Silva R, Cisbani G, Drouin-Ouellet J, Spillantini MG, Cicchetti F, Barker RA. The role of tau in the pathological process and clinical expression of Huntington's disease. Brain : a Journal of Neurology. 138: 1907-18. PMID 25953777 DOI: 10.1093/brain/awv107  0.92
2015 Mason S, Barker RA. Progress in Huntington's disease: the search for markers of disease onset and progression. Journal of Neurology. PMID 25794860 DOI: 10.1007/s00415-015-7700-0  0.92
2015 Schwab LC, Garas SN, Drouin-Ouellet J, Mason SL, Stott SR, Barker RA. Dopamine and Huntington's disease. Expert Review of Neurotherapeutics. 15: 445-58. PMID 25773746 DOI: 10.1586/14737175.2015.1025383  0.92
2015 Mason SL, Zhang J, Begeti F, Guzman NV, Lazar AS, Rowe JB, Barker RA, Hampshire A. The role of the amygdala during emotional processing in Huntington's disease: from pre-manifest to late stage disease. Neuropsychologia. 70: 80-9. PMID 25700742 DOI: 10.1016/j.neuropsychologia.2015.02.017  0.92
2015 Loftus AM, Bucks RS, Thomas M, Kane R, Timms C, Barker RA, Gasson N. Retrospective assessment of movement disorder society criteria for mild cognitive impairment in Parkinson's disease. Journal of the International Neuropsychological Society : Jins. 21: 137-45. PMID 25666735 DOI: 10.1017/S1355617715000041  0.92
2015 Arsenault D, Drouin-Ouellet J, Saint-Pierre M, Petrou P, Dubois M, Kriz J, Barker RA, Cicchetti A, Cicchetti F. A novel combinational approach of microstimulation and bioluminescence imaging to study the mechanisms of action of cerebral electrical stimulation in mice. The Journal of Physiology. 593: 2257-78. PMID 25653107 DOI: 10.1113/jphysiol.2014.287243  0.92
2015 Winder-Rhodes SE, Hampshire A, Rowe JB, Peelle JE, Robbins TW, Owen AM, Barker RA. Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals. Neurobiology of Aging. 36: 1519-28. PMID 25577413 DOI: 10.1016/j.neurobiolaging.2014.12.006  0.92
2015 Drouin-Ouellet J, St-Amour I, Saint-Pierre M, Lamontagne-Proulx J, Kriz J, Barker RA, Cicchetti F. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18. PMID 25522431 DOI: 10.1093/ijnp/pyu103  0.92
2015 Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Improving response inhibition in Parkinson's disease with atomoxetine. Biological Psychiatry. 77: 740-8. PMID 24655598 DOI: 10.1016/j.biopsych.2014.01.024  0.92
2015 Mason S, Barker RA. Rating Apathy in Huntington's Disease: Patients and Companions Agree Journal of Huntington's Disease. 4: 49-59. DOI: 10.3233/JHD-140133  0.92
2015 Cummins G, Zandi M, Barker RA. Movement disorders and psychiatry: Five new things Neurology: Clinical Practice. 5: 143-149. DOI: 10.1212/CPJ.0000000000000113  0.92
2015 Musso M, Westervelt HJ, Long JD, Morgan E, Woods SP, Smith MM, Lu W, Paulsen JS, Cross S, Ryan P, Epping EA, Chiu E, Preston J, Goh A, Antonopoulos S, ... ... Barker RA, et al. Intra-individual variability in prodromal Huntington disease and its relationship to genetic burden Journal of the International Neuropsychological Society. 21: 8-21. DOI: 10.1017/S1355617714001076  0.92
2014 Barker RA. Developing stem cell therapies for Parkinson's disease: waiting until the time is right. Cell Stem Cell. 15: 539-42. PMID 25517462 DOI: 10.1016/j.stem.2014.09.016  0.92
2014 Kuan WL, Kasis A, Yuan Y, Mason SL, Lazar AS, Barker RA, Goncalves J. Modelling the natural history of Huntington's disease progression. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 25515501 DOI: 10.1136/jnnp-2014-308153  0.92
2014 Paulsen JS, Long JD, Ross CA, Harrington DL, Erwin CJ, Williams JK, Westervelt HJ, Johnson HJ, Aylward EH, Zhang Y, Bockholt HJ, Barker RA. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study. The Lancet. Neurology. 13: 1193-201. PMID 25453459 DOI: 10.1016/S1474-4422(14)70238-8  0.92
2014 Videnovic A, Breen DP, Barker RA, Zee PC. The central clock in patients with Parkinson disease--reply. Jama Neurology. 71: 1456-7. PMID 25383776 DOI: 10.1001/jamaneurol.2014.2711  0.92
2014 Drouin-Ouellet J, Barker RA. Stem cell therapies for Parkinson's disease: are trials just around the corner? Regenerative Medicine. 9: 553-5. PMID 25372072 DOI: 10.2217/rme.14.43  0.92
2014 Moore SF, Guzman NV, Mason SL, Williams-Gray CH, Barker RA. Which patients with Parkinson's disease participate in clinical trials? One centre's experiences with a new cell based therapy trial (TRANSEURO). Journal of Parkinson's Disease. 4: 671-6. PMID 25170676 DOI: 10.3233/JPD-140432  0.92
2014 Barker RA, Williams-Gray CH. Mild cognitive impairment and Parkinson's disease--something to remember. Journal of Parkinson's Disease. 4: 651-6. PMID 25147139 DOI: 10.3233/JPD-140427  0.92
2014 Zhao JW, Dyson SC, Kriegel C, Tyers P, He X, Fahmy TM, Metcalfe SM, Barker RA. Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease. Disease Models & Mechanisms. 7: 1193-203. PMID 25085990 DOI: 10.1242/dmm.015859  0.92
2014 Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ, ... ... Barker RA, et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain : a Journal of Neurology. 137: 2743-58. PMID 25080285 DOI: 10.1093/brain/awu201  0.92
2014 Barker RA, Cicchetti F. Neurodegenerative disorders: the Glia way forward. Frontiers in Pharmacology. 5: 157. PMID 25076908 DOI: 10.3389/fphar.2014.00157  0.92
2014 Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, Collerton D, Taylor JP, Burn DJ. Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life. Parkinsonism & Related Disorders. 20: 1071-5. PMID 25074728 DOI: 10.1016/j.parkreldis.2014.07.004  0.92
2014 Cicchetti F, Barker RA. The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? Frontiers in Pharmacology. 5: 139. PMID 25071571 DOI: 10.3389/fphar.2014.00139  0.92
2014 Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet (London, England). 384: 1196-205. PMID 24928805 DOI: 10.1016/S0140-6736(14)60683-8  0.92
2014 Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, Collerton D, Taylor JP, Burn DJ. Quality of life and mild cognitive impairment in early Parkinson's disease: does subtype matter? Journal of Parkinson's Disease. 4: 331-6. PMID 24919824 DOI: 10.3233/JPD-140390  0.92
2014 Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, Sahakian BJ, Robbins TW. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain : a Journal of Neurology. 137: 1986-97. PMID 24893708 DOI: 10.1093/brain/awu117  0.92
2014 Ali FR, Cheng K, Kirwan P, Metcalfe S, Livesey FJ, Barker RA, Philpott A. The phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and maturation in vivo and in vitro. Development (Cambridge, England). 141: 2216-24. PMID 24821983 DOI: 10.1242/dev.106377  0.92
2014 Cicchetti F, Lacroix S, Cisbani G, Vallières N, Saint-Pierre M, St-Amour I, Tolouei R, Skepper JN, Hauser RA, Mantovani D, Barker RA, Freeman TB. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Annals of Neurology. 76: 31-42. PMID 24798518 DOI: 10.1002/ana.24174  0.92
2014 Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, Nance MA, Erwin CJ, Westervelt HJ, Harrington DL, Bockholt HJ, Zhang Y, McCusker EA, Chiu EM, Panegyres PK, et al. Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study. Frontiers in Aging Neuroscience. 6: 78. PMID 24795630 DOI: 10.3389/fnagi.2014.00078  0.92
2014 Goldman JG, Williams-Gray C, Barker RA, Duda JE, Galvin JE. The spectrum of cognitive impairment in Lewy body diseases. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 608-21. PMID 24757110 DOI: 10.1002/mds.25866  0.92
2014 Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA. Sleep and circadian rhythm regulation in early Parkinson disease. Jama Neurology. 71: 589-95. PMID 24687146 DOI: 10.1001/jamaneurol.2014.65  0.92
2014 Buttery PC, Barker RA. Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? The Journal of Comparative Neurology. 522: 2802-16. PMID 24610597 DOI: 10.1002/cne.23577  0.92
2014 Herva ME, Zibaee S, Fraser G, Barker RA, Goedert M, Spillantini MG. Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). The Journal of Biological Chemistry. 289: 11897-905. PMID 24584936 DOI: 10.1074/jbc.M113.542340  0.92
2014 Huefner A, Septiadi D, Wilts BD, Patel II, Kuan WL, Fragniere A, Barker RA, Mahajan S. Gold nanoparticles explore cells: cellular uptake and their use as intracellular probes. Methods (San Diego, Calif.). 68: 354-63. PMID 24583117 DOI: 10.1016/j.ymeth.2014.02.006  0.92
2014 Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain : a Journal of Neurology. 137: 1145-55. PMID 24578545 DOI: 10.1093/brain/awu032  0.92
2014 Collins LM, Lazic SE, Barker RA. A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington's disease. Bmc Neurology. 14: 35. PMID 24564568 DOI: 10.1186/1471-2377-14-35  0.92
2014 Choi ML, Begeti F, Oh JH, Lee SY, O'Keeffe GC, Clelland CD, Tyers P, Cho ZH, Kim YB, Barker RA. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease. Neurobiology of Disease. 66: 19-27. PMID 24561069 DOI: 10.1016/j.nbd.2014.02.004  0.92
2014 Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, ... ... Barker RA, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 383: 1138-46. PMID 24412048 DOI: 10.1016/S0140-6736(13)61939-X  0.92
2014 Stott SR, Barker RA. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease. The European Journal of Neuroscience. 39: 1042-56. PMID 24372914 DOI: 10.1111/ejn.12459  0.92
2014 Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank MJ, Nombela C, Winder-Rhodes S, Evans JR, Rowe JB, Mollenhauer B, Kruse N, Hudson G, Chinnery PF, O'Brien JT, ... ... Barker RA, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 82: 308-16. PMID 24363137 DOI: 10.1212/WNL.0000000000000066  0.92
2014 Barker RA, Mason SL. Neurodegenerative disease: Mapping the natural history of Huntington disease. Nature Reviews. Neurology. 10: 12-3. PMID 24323048 DOI: 10.1038/nrneurol.2013.253  0.92
2014 Moore SF, Barker RA. Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease. Parkinsonism & Related Disorders. 20: S104-7. PMID 24262158 DOI: 10.1016/S1353-8020(13)70026-9  0.92
2014 Long JD, Paulsen JS, Marder K, Zhang Y, Kim JI, Mills JA. Tracking motor impairments in the progression of Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 311-9. PMID 24150908 DOI: 10.1002/mds.25657  0.92
2014 Duncan GW, Khoo TK, Yarnall AJ, O'Brien JT, Coleman SY, Brooks DJ, Barker RA, Burn DJ. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 195-202. PMID 24123307 DOI: 10.1002/mds.25664  0.92
2014 Duncan GW, Khoo TK, Coleman SY, Brayne C, Yarnall AJ, O'Brien JT, Barker RA, Burn DJ. The incidence of Parkinson's disease in the North-East of England. Age and Ageing. 43: 257-63. PMID 23880142 DOI: 10.1093/ageing/aft091  0.92
2014 Ali F, Stott SR, Barker RA. Stem cells and the treatment of Parkinson's disease. Experimental Neurology. 260: 3-11. PMID 23298521 DOI: 10.1016/j.expneurol.2012.12.017  0.92
2014 Younes L, Ratnanather JT, Brown T, Aylward E, Nopoulos P, Johnson H, Magnotta VA, Paulsen JS, Margolis RL, Albin RL, Miller MI, Ross CA. Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Human Brain Mapping. 35: 792-809. PMID 23281100 DOI: 10.1002/hbm.22214  0.92
2014 Kehagia AA, Barker RA, Robbins TW. Revisiting the effects of Parkinson's disease and frontal lobe lesions on task switching: the role of rule reconfiguration. Journal of Neuropsychology. 8: 53-74. PMID 23279799 DOI: 10.1111/jnp.12004  0.92
2014 Barker RA. Editorial Neuropathology and Applied Neurobiology. 40: 1-2. DOI: 10.1111/nan.12106  0.92
2014 Barker RA. What have open label studies of cell based therapies for parkinson's disease told us, if anything? Basal Ganglia. 4: 85-87. DOI: 10.1016/j.baga.2014.06.003  0.92
2013 Drouin-Ouellet J, Barker RA. The challenges of administering cell-based therapies to patients with Parkinson's disease. Neuroreport. 24: 1000-4. PMID 24145775 DOI: 10.1097/WNR.0000000000000057  0.92
2013 Whitworth SR, Loftus AM, Skinner TC, Gasson N, Barker RA, Bucks RS, Thomas MG. Personality affects aspects of health-related quality of life in Parkinson's disease via psychological coping strategies. Journal of Parkinson's Disease. 3: 45-53. PMID 23938310 DOI: 10.3233/JPD-120149  0.92
2013 Begeti F, Tan AY, Cummins GA, Collins LM, Guzman NV, Mason SL, Barker RA. The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease. Journal of Neurology. 260: 2777-85. PMID 23922130 DOI: 10.1007/s00415-013-7061-5  0.92
2013 Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 1258-64. PMID 23781007 DOI: 10.1136/jnnp-2013-305277  0.92
2013 Barker RA, Stacy M, Brundin P. A new approach to disease-modifying drug trials in Parkinson's disease. The Journal of Clinical Investigation. 123: 2364-5. PMID 23728166 DOI: 10.1172/JCI69690  0.92
2013 Barker RA, de Beaufort I. Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. Progress in Neurobiology. 110: 63-73. PMID 23665410 DOI: 10.1016/j.pneurobio.2013.04.003  0.92
2013 Hudson G, Nalls M, Evans JR, Breen DP, Winder-Rhodes S, Morrison KE, Morris HR, Williams-Gray CH, Barker RA, Singleton AB, Hardy J, Wood NE, Burn DJ, Chinnery PF. Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology. 80: 2042-8. PMID 23645593 DOI: 10.1212/WNL.0b013e318294b434  0.92
2013 Bianco P, Barker R, Brüstle O, Cattaneo E, Clevers H, Daley GQ, De Luca M, Goldstein L, Lindvall O, Mummery C, Robey PG, Sattler de Sousa E Brito C, Smith A. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. The Embo Journal. 32: 1489-95. PMID 23644381 DOI: 10.1038/emboj.2013.114  0.92
2013 Huefner A, Kuan WL, Barker RA, Mahajan S. Intracellular SERS nanoprobes for distinction of different neuronal cell types. Nano Letters. 13: 2463-70. PMID 23638825 DOI: 10.1021/nl400448n  0.92
2013 Ellul MA, Cross J, Barker RA. L-dopa responsive parkinsonism secondary to a subdural haematoma. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 20: 1022-4. PMID 23618681 DOI: 10.1016/j.jocn.2012.06.019  0.92
2013 Breen DP, Evans JR, Farrell K, Brayne C, Barker RA. Determinants of delayed diagnosis in Parkinson's disease. Journal of Neurology. 260: 1978-81. PMID 23572347 DOI: 10.1007/s00415-013-6905-3  0.92
2013 Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M, Hauser RA, Barker RA, Cicchetti F. Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain : a Journal of Neurology. 136: 433-43. PMID 23378216 DOI: 10.1093/brain/aws359  0.92
2013 Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 657-65. PMID 23345280 DOI: 10.1136/jnnp-2012-302441  0.92
2013 Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O'Brien JT, Brooks DJ, Barker RA, Burn DJ. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 80: 276-81. PMID 23319473 DOI: 10.1212/WNL.0b013e31827deb74  0.92
2013 Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, Barker RA, Rowe JB. The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 544-51. PMID 23303961 DOI: 10.1136/jnnp-2012-303618  0.92
2013 Delli Carri A, Onorati M, Lelos MJ, Castiglioni V, Faedo A, Menon R, Camnasio S, Vuono R, Spaiardi P, Talpo F, Toselli M, Martino G, Barker RA, Dunnett SB, Biella G, et al. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development (Cambridge, England). 140: 301-12. PMID 23250204 DOI: 10.1242/dev.084608  0.92
2013 Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, Ziman MR. The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 20: 1325-9. PMID 23216520 DOI: 10.1111/ene.12053  0.92
2013 Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA. Excessive daytime sleepiness and its risk factors in incident Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 233-4. PMID 23184153 DOI: 10.1136/jnnp-2012-304097  0.92
2013 Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neuro-Degenerative Diseases. 11: 79-92. PMID 23038420 DOI: 10.1159/000341998  0.92
2013 Ribeiro D, Laguna Goya R, Ravindran G, Vuono R, Parish CL, Foldi C, Piroth T, Yang S, Parmar M, Nikkhah G, Hjerling-Leffler J, Lindvall O, Barker RA, Arenas E. Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. Neurobiology of Disease. 49: 118-27. PMID 22940632 DOI: 10.1016/j.nbd.2012.08.006  0.92
2013 Hughes LE, Altena E, Barker RA, Rowe JB. Perseveration and choice in Parkinson's disease: the impact of progressive frontostriatal dysfunction on action decisions. Cerebral Cortex (New York, N.Y. : 1991). 23: 1572-81. PMID 22661404 DOI: 10.1093/cercor/bhs144  0.92
2013 Drouin-Ouellet J, Collins LM, Barker RA. Can patient-specific transdifferentiated neuronal cells help us understand the cellular pathology of Parkinson"s disease? Future Neurology. 8: 605-607. DOI: 10.2217/fnl.13.46  0.92
2012 Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MD, Misbahuddin A, Chinnery PF, Burn DJ, Clarke CE, Marion MH, Lewthwaite AJ, Nicholl DJ, Wood NW, Morrison KE, Williams-Gray CH, ... ... Barker RA, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1522-9. PMID 22956510 DOI: 10.1002/mds.25132  0.92
2012 Wu K, O'Keeffe D, Politis M, O'Keeffe GC, Robbins TW, Bose SK, Brooks DJ, Piccini P, Barker RA. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain : a Journal of Neurology. 135: 2449-57. PMID 22843413 DOI: 10.1093/brain/aws157  0.92
2012 McColgan P, Evans JR, Breen DP, Mason SL, Barker RA, Williams-Gray CH. Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1173-7. PMID 22733390 DOI: 10.1002/mds.25084  0.92
2012 Rae CL, Correia MM, Altena E, Hughes LE, Barker RA, Rowe JB. White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage. 62: 1675-84. PMID 22713671 DOI: 10.1016/j.neuroimage.2012.06.012  0.92
2012 Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, Piantadosi S, Comstock Rick A, Federoff HJ. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. The Lancet. Neurology. 11: 643-50. PMID 22710757 DOI: 10.1016/S1474-4422(12)70064-9  0.92
2012 Höglinger GU, Barker RA, Hagg T, Arias-Carrión O, Caldwell MA, Hirsch EC. Quantitative evaluation of the human subventricular zone. Brain : a Journal of Neurology. 135: e221, 1-4; author re. PMID 22539257 DOI: 10.1093/brain/aws087  0.92
2012 Antoniades CA, Buttery P, FitzGerald JJ, Barker RA, Carpenter RH, Watts C. Deep brain stimulation: eye movements reveal anomalous effects of electrode placement and stimulation. Plos One. 7: e32830. PMID 22427894 DOI: 10.1371/journal.pone.0032830  0.92
2006 Farrington M, Wreghitt TG, Lever AM, Dunnett SB, Rosser AE, Barker RA. Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature. Cell Transplantation. 15: 279-94. PMID 16898222 DOI: 10.1016/B978-012369415-7/50025-9  1
2004 Harrower TP, Richards A, Cruz G, Copeman L, Dunnett SB, Barker RA. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue. Xenotransplantation. 11: 60-71. PMID 14962294 DOI: 10.1111/j.1399-3089.2004.00084.x  0.92
2003 Hurelbrink CB, Tyers P, Armstrong RJE, Dunnett SB, Barker RA, Rosser AE. Long-Term Hibernation of Human Fetal Striatal Tissue does Not Adversely Affect its Differentiation In Vitro or Graft Survival: Implications for Clinical Trials in Huntington's Disease. Cell Transplantation. 12: 687-695. PMID 28858586 DOI: 10.3727/000000003108747307  1
2003 Hurelbrink CB, Tyers P, Armstrong RJ, Dunnett SB, Barker RA, Rosser AE. Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. Cell Transplantation. 12: 687-95. PMID 14653616  0.92
2003 Rosser AE, Barker RA, Armstrong RJ, Elneil S, Jain M, Hurelbrink CB, Prentice A, Carne C, Thornton S, Hutchinson H, Dunnett SB. Staging and preparation of human fetal striatal tissue for neural transplantation in Huntington's disease. Cell Transplantation. 12: 679-86. PMID 14653615  0.92
2003 Björklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, Levivier M, Peschanski M, Studer L, Barker R. Neural transplantation for the treatment of Parkinson's disease. The Lancet. Neurology. 2: 437-45. PMID 12849125 DOI: 10.1016/S1474-4422(03)00442-3  0.92
2003 Armstrong RJ, Tyers P, Jain M, Richards A, Dunnett SB, Rosser AE, Barker RA. Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease. Experimental Brain Research. 151: 204-17. PMID 12783147 DOI: 10.1007/s00221-003-1491-8  0.92
2003 Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain : a Journal of Neurology. 126: 1127-35. PMID 12690052 DOI: 10.1093/brain/awg119  0.92
2002 Rosser AE, Barker RA, Harrower T, Watts C, Farrington M, Ho AK, Burnstein RM, Menon DK, Gillard JH, Pickard J, Dunnett SB. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. Journal of Neurology, Neurosurgery, and Psychiatry. 73: 678-85. PMID 12438470 DOI: 10.1136/jnnp.73.6.678  0.92
2002 Armstrong RJ, Hurelbrink CB, Tyers P, Ratcliffe EL, Richards A, Dunnett SB, Rosser AE, Barker RA. The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease. Experimental Neurology. 175: 98-111. PMID 12009763 DOI: 10.1006/exnr.2002.7889  0.92
2002 Hurelbrink CB, Armstrong RJ, Dunnett SB, Rosser AE, Barker RA. Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. The European Journal of Neuroscience. 15: 1255-66. PMID 11982636 DOI: 10.1046/j.1460-9568.2002.01959.x  0.92
2002 Harrower TP, Richards A, Cruz G, Copeman L, Dunnett SB, Barker RA. Alpha Gal is widely expressed in embryonic porcine stem cells and neural tissue. Neuroreport. 13: 481-5. PMID 11930166  0.92
2001 Armstrong RJ, Rosser AE, Dunnett SB, Barker RA. Neural stem cell technology as a novel treatment for Parkinson's disease. Methods in Molecular Medicine. 62: 289-307. PMID 21318784 DOI: 10.1385/1-59259-142-6:289  1
2001 Armstrong RJ, Harrower TP, Hurelbrink CB, McLaughin M, Ratcliffe EL, Tyers P, Richards A, Dunnett SB, Rosser AE, Barker RA. Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells. Neuroscience. 106: 201-16. PMID 11564430 DOI: 10.1016/S0306-4522(01)00273-1  0.92
2001 Hurelbrink CB, Armstrong RJ, Luheshi LM, Dunnett SB, Rosser AE, Barker RA. Death of dopaminergic neurons in vitro and in nigral grafts: reevaluating the role of caspase activation. Experimental Neurology. 171: 46-58. PMID 11520120 DOI: 10.1006/exnr.2001.7749  0.92
2000 Hurelbrink CB, Armstrong RJE, Barker RA, Dunnett SB, Rosser AE. Hibernated Human Fetal Striatal Tissue: Successful Transplantation in a Rat Model of Huntington's Disease. Cell Transplantation. 9: 743-749. PMID 28886291 DOI: 10.1177/096368970000900601  1
2000 Hurelbrink CB, Armstrong RJ, Barker RA, Dunnett SB, Rosser AE. Hibernated human fetal striatal tissue: successful transplantation in a rat model of Huntington's disease. Cell Transplantation. 9: 743-9. PMID 11202561  0.92
2000 Barker RA, Ratcliffe E, McLaughlin M, Richards A, Dunnett SB. A role for complement in the rejection of porcine ventral mesencephalic xenografts in a rat model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 3415-24. PMID 10777804  1
1999 Barker RA, Ratcliffe E, Richards A, Dunnett SB. Fetal porcine dopaminergic cell survival in vitro and its relationship to embryonic age. Cell Transplantation. 8: 593-9. PMID 10701488  1
1999 Barker RA, Dunnett SB. Functional integration of neural grafts in Parkinson's disease. Nature Neuroscience. 2: 1047-8. PMID 10570477 DOI: 10.1038/15969  1
1999 Barker RA, Dunnett SB, Richards A. The rejection of neural xenotransplants: a role for antibodies. Transplantation. 68: 1091-2. PMID 10551631  1
1998 Dunnett SB, Torres EM, Richards H, Barker RA. Effects of surgical anaesthesia on the viability of nigral grafts in the rat striatum. Cell Transplantation. 7: 567-72. PMID 9853585 DOI: 10.1016/S0963-6897(98)00038-4  0.92
1997 Annett LE, Torres EM, Clarke DJ, Ishida Y, Barker RA, Ridley RM, Baker HF, Dunnett SB. Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. Cell Transplantation. 6: 557-69. PMID 9440865 DOI: 10.1016/S0963-6897(97)00079-1  0.92
1996 Fricker RA, Barker RA, Fawcett JW, Dunnett SB. A comparative study of preparation techniques for improving the viability of striatal grafts using vital stains, in vitro cultures, and in vivo grafts. Cell Transplantation. 5: 599-611. PMID 8951218  1
1996 Barker RA, Dunnett SB, Faissner A, Fawcett JW. The time course of loss of dopaminergic neurons and the gliotic reaction surrounding grafts of embryonic mesencephalon to the striatum. Experimental Neurology. 141: 79-93. PMID 8797670 DOI: 10.1006/exnr.1996.0141  1
1995 Fawcett JW, Barker RA, Dunnett SB. Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. Experimental Brain Research. 106: 275-82. PMID 8566192  1
1995 Barker RA, Fricker RA, Abrous DN, Fawcett J, Dunnett SB. A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts. Cell Transplantation. 4: 173-200. PMID 7539699  1
1994 Barker R, Dunnett SB. Ibotenic acid lesions of the striatum reduce drug-induced rotation in the 6-hydroxydopamine-lesioned rat. Experimental Brain Research. 101: 365-74. PMID 7851507  1
Show low-probability matches.